Role of chitosan based nanomedicines in the treatment of chronic respiratory diseases.
Int J Biol Macromol
; 185: 20-30, 2021 Aug 31.
Article
in English
| MEDLINE | ID: covidwho-1260751
ABSTRACT
Chitosan-loaded nanomedicines provide a greater opportunity for the treatment of respiratory diseases. Natural biopolymer chitosan and its derivatives have a large number of proven pharmacological actions like antioxidant, wound healing, immuno-stimulant, hypocholesterolemic, antimicrobial, obesity treatment, anti-inflammatory, anticancer, bone tissue engineering, antifungal, regenerative medicine, anti-diabetic and mucosal adjuvant, etc. which attracted its use in the pharmaceutical industry. As compared to other polysaccharides, chitosan has excellent mucoadhesive characteristics, less viscous, easily modified into the chemical and biological molecule and gel-forming property due to which the drugs retain in the respiratory tract for a longer period of time providing enhanced therapeutic action of the drug. Chitosan-based nanomedicines would have the greatest effect when used to transport poor water soluble drugs, macromolecules like proteins, and peptides through the lungs. In this review, we highlight and discuss the role of chitosan and its nanomedicines in the treatment of chronic respiratory diseases such as pneumonia, asthma, COPD, lung cancer, tuberculosis, and COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Drug Carriers
/
Chitosan
/
Nanomedicine
/
SARS-CoV-2
/
COVID-19
/
COVID-19 Drug Treatment
Type of study:
Observational study
Limits:
Animals
/
Humans
Language:
English
Journal:
Int J Biol Macromol
Year:
2021
Document Type:
Article
Affiliation country:
J.ijbiomac.2021.06.035
Similar
MEDLINE
...
LILACS
LIS